Things worth knowing about "Atovaquone-Proguanil"
Atovaquone-proguanil is a combination medication used to prevent and treat malaria. It is commonly recommended for travelers visiting malaria-endemic regions.
What is Atovaquone-Proguanil?
Atovaquone-proguanil is a combination antimalarial drug containing two active ingredients: atovaquone and proguanil. It is used for both the prevention (prophylaxis) and treatment of uncomplicated falciparum malaria caused by the parasite Plasmodium falciparum. The medication is widely known under the brand name Malarone® and is one of the most commonly prescribed antimalarial agents for international travelers.
Indications
Atovaquone-proguanil is used in the following situations:
- Malaria prophylaxis for travelers: Prevention of malaria infection when traveling to regions with known transmission risk, particularly in tropical and subtropical areas of Africa, Asia, and South America.
- Treatment of uncomplicated falciparum malaria: Management of confirmed Plasmodium falciparum infection without severe complications.
Mechanism of Action
The two active components work synergistically by targeting different stages and pathways within the malaria parasite:
Atovaquone
Atovaquone disrupts the mitochondrial electron transport chain of Plasmodium falciparum by inhibiting Complex III (cytochrome bc1 complex). This blocks the parasite's ability to produce energy, ultimately leading to its death.
Proguanil
Proguanil is converted in the body to its active metabolite cycloguanil, which inhibits dihydrofolate reductase - an enzyme essential for folate synthesis in the parasite. In addition, proguanil independently potentiates the collapse of the mitochondrial membrane potential caused by atovaquone.
This dual mechanism of action makes the combination highly effective and significantly reduces the likelihood of drug resistance developing.
Dosage and Administration
Dosage depends on age, body weight, and the purpose of use (prophylaxis or treatment):
Prophylaxis (Prevention)
- Begin taking the medication 1 to 2 days before entering the malaria-endemic area.
- Take once daily throughout the entire stay.
- Continue for 7 days after returning from the risk area.
- Always take with food or a milky drink to improve absorption and reduce gastrointestinal side effects.
Treatment
- In adults, the standard dose is typically 4 tablets once daily for 3 consecutive days.
- In children, dosage is adjusted according to body weight.
Side Effects
Atovaquone-proguanil is generally well tolerated. Possible side effects include:
Common Side Effects
- Headache
- Nausea and vomiting
- Abdominal pain or diarrhea
- Dizziness
Rare Side Effects
- Skin rash or itching
- Elevated liver enzymes (transaminases)
- Mouth ulcers
- In very rare cases: allergic reactions
Individuals with known hypersensitivity to either active ingredient should not use this medication. Persistent or severe side effects should be evaluated by a healthcare professional.
Contraindications and Precautions
- Severe renal impairment: Atovaquone-proguanil should not be used for prophylaxis in patients with severe kidney disease.
- Pregnancy and breastfeeding: Use during pregnancy, particularly in the first trimester, and during breastfeeding is generally not recommended due to limited safety data. The decision should be made in consultation with a physician.
- Children under 11 kg body weight: The medication is not approved for use in very young or small children.
- Drug interactions: Concurrent use of rifampicin, tetracycline, or metoclopramide may reduce the effectiveness of atovaquone and should be avoided where possible.
Comparison with Other Antimalarials
Compared to other antimalarial medications such as mefloquine or doxycycline, atovaquone-proguanil offers several advantages:
- Shorter post-travel dosing period (only 7 days after return, compared to 4 weeks with doxycycline or mefloquine).
- Can be started just 1 to 2 days before travel, offering flexibility.
- Favorable tolerability profile, especially the absence of neuropsychiatric side effects associated with mefloquine.
However, the cost of atovaquone-proguanil is generally higher than that of alternative prophylactic options. The choice of the most appropriate antimalarial should always be made in consultation with a travel medicine or tropical disease specialist.
References
- World Health Organization (WHO): International Travel and Health. Geneva, updated edition. Available at: https://www.who.int/publications/i/item/9789240003088
- Centers for Disease Control and Prevention (CDC): Malaria - Choosing a Drug to Prevent Malaria. Atlanta. Available at: https://www.cdc.gov/malaria/travelers/drugs.html
- Overbosch D et al.: Atovaquone-Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers. Clinical Infectious Diseases, 33(7):1015-1021, 2001.